Ardelyx vs Krystal Biotech
Ardelyx and Krystal Biotech are similar in size: $407m and $389m of revenue in their latest fiscal years. Krystal Biotech grew faster (33.9% against 22.1%). Krystal Biotech kept more of each dollar of sales as profit: a net margin of 52.6% against -15.1%. Krystal Biotech carries less debt relative to equity (0.0% against 121.5%).
| Latest fiscal year | ArdelyxARDX, 2025 | Krystal BiotechKRYS, 2025 |
|---|---|---|
| Revenue | $407m | $389m |
| Revenue growth | 22.1% | 33.9% |
| Net income | −$61.6m | $205m |
| Operating margin | -10.1% | 41.5% |
| Net margin | -15.1% | 52.6% |
| Return on equity | -36.2% | 18.9% |
| Free cash flow | −$44.0m | $189m |
| Cash | $68.0m | $496m |
| Total debt | $203m | $0 |
| Debt to equity | 121.5% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 489 | — |
| Market value | $755m | $9.00bn |
| Price vs our value range | — | Within our value range |
| Moat score | 24 (Weak) | — |
| Insider trades, 12 months | 1 buys, 77 sales | 0 buys, 142 sales |